Incidence of chemotherapy-induced nausea and vomiting (CINV) after highly and moderately emetogenic therapy in the era of NK-1 inhibitors - perception versus reality

被引：0
|
作者：
Perez-Altozano, J. [1 ]
Majem, M. [1 ]
Calvo, N. [1 ]
Moreno, E. [1 ]
Feliu, A. [1 ]
Gich, I. [1 ]
Mangues, A. [1 ]
Barnadas, A. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70629-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).
    Rapoport, Bernardo Leon
    Schwartzberg, Lee Steven
    Chasen, Martin Robert
    Powers, Daniel
    Arora, Sujata
    Navari, Rudolph M.
    Schnadig, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [22] Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)
    Schwartzberg, Lee
    Szabo, Stephen
    Gilmore, James
    Haislip, Sally
    Jackson, James
    Jain, Gagan
    Balu, Sanjeev
    Buchner, Deborah
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (04) : 837 - 845
  • [23] Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
    Yolanda Escobar
    Gerardo Cajaraville
    Juan Antonio Virizuela
    Rosa Álvarez
    Andrés Muñoz
    Olatz Olariaga
    María José Tamés
    Begoña Muros
    María Jose Lecumberri
    Jaime Feliu
    Purificación Martínez
    Juan Carlos Adansa
    María José Martínez
    Rafael López
    Ana Blasco
    Pere Gascón
    Virginia Calvo
    Pablo Luna
    Joaquín Montalar
    Patricia Del Barrio
    María Victoria Tornamira
    Supportive Care in Cancer, 2015, 23 : 2841 - 2841
  • [24] The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.
    Navari, Rudolph M.
    Nagy, Cindy K.
    Gray, Sarah E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
    Thomas A. Burke
    Tami Wisniewski
    Frank R. Ernst
    Supportive Care in Cancer, 2011, 19 : 131 - 140
  • [26] Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
    Burke, Thomas A.
    Wisniewski, Tami
    Ernst, Frank R.
    SUPPORTIVE CARE IN CANCER, 2011, 19 (01) : 131 - 140
  • [27] Efficacy and safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy.
    Fein, Luis Enrique
    Poma, Allen
    Hedley, Mary Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] ANALYSIS OF PALONOSETRON VS ONDANSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PEDIATRIC PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Kovacs, G.
    Wachtel, A. E.
    Basharova, E. V.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S108 - S108
  • [29] Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV).
    Tremont-Lukats, IW
    González-Barboteo, J
    Bruera, E
    Brescia, FJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 740S - 740S
  • [30] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Gao, Ai
    Guan, Shasha
    Sun, Yinjuan
    Wang, Lingling
    Meng, Fanlu
    Liu, Xia
    Gu, Liyan
    Li, Guo
    Zhong, Diansheng
    Zhang, Linlin
    BMC CANCER, 2023, 23 (01)
12345